Product logins

Find logins to all Clarivate products below.


Open Surgery Instruments | Market Insights | Europe | 2022

Procedure deferrals due to the COVID-19 pandemic severely impacted the European open surgery instrument market in 2020, and the elective nature of many postponed procedures will hinder the pace of recovery to some extent. Nonetheless, following short-term disruption due to the global pandemic, the European open surgery instrument market will grow marginally throughout the remainder of the forecast period. Revenue growth will be supported by the continued uptake of innovative premium-priced products, although rising laparoscopic procedure penetration—and consequently declining open procedure volumes—will hamper market expansion. 

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for open surgery instruments in Europe across an 11-year period.

Related Medtech Insights Reports

Report
Biosurgical Agents – Market Insights – Latin America
The Latin American biosurgical agent market will grow modestly through 2034; although demand for biosurgical agents will rise—supported by favorable regional demographics, expanded indication…
Report
Biosurgical Agents – Market Insights – Japan
The Japanese biosurgical agent market is projected to demonstrate a modest growth through 2034, driven by the rising volume of surgical procedures, increasing physician awareness of the clinical…
Report
Biosurgical Agents – Market Insights – US
The biosurgical agent market in the US will experience modest growth through 2034. This growth will be fueled by rising surgical procedure volumes that require biosurgical agent and strong…
Report
Biosurgical Agents – Market Insights – Europe
The Europe biosurgical agent market will exhibit modest growth over the forecast period. This expansion will be fueled by a continued preference for biosurgical agents over alternative solutions,…
Report
Biosurgical Agents – Market Insights – Asia Pacific
The biosurgical agent market in Asia Pacific will experience modest growth through 2034, driven by rising surgical procedure volumes and expanding use of biosurgical agents across a broader range…